http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights
-
Foundation Medicine Announces Timing for First Quarter 2017 Financial Results and Conference Call
-
Bristol-Myers Squibb (BMY), Foundation Medicine (FMI) Enter Pact to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
-
Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
-
Foundation Medicine (FMI) Receives Medicare Payment for Comprehensive Genomic Profiling Assay Used in NSCLC
-
Foundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne®, the Company’s Comprehensive Genomic Profiling Assay
-
Foundation Medicine to Present at Cowen and Company’s 37th Annual Healthcare Conference
-
Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook
-
Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2016 Financial Results and Conference Call
-
Foundation Medicine (FMI) Q4 Preliminary Revs $28.8M, Vs. $30.33M Consensus
-
Foundation Medicine Reports Preliminary 2016 Results
-
Foundation Medicine (FMI) Says Troy Cox to Succeed Michael Pellini as CEO
-
Foundation Medicine Announces Executive Leadership Transition
-
Foundation Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference
-
Foundation Medicine (FMI) Announces FDA Approval of FoundationFocus, Companion Diagnostic for Rubraca
-
Foundation Medicine Receives FDA Approval of FoundationFocus™ CDxBRCA as a Companion Diagnostic for Rubraca™ (rucaparib) for the Treatment of Women with Ovarian Cancer
-
Flatiron Health and Foundation Medicine Unveil Powerful Oncology Information Resource to Advance Precision Medicine
-
Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights
-
Foundation Medicine and Sarah Cannon Collaborate to Advance Personalized Medicine for Patients with Cancer
-
Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors
-
Foundation Medicine Announces Timing for Third Quarter 2016 Financial Results and Conference Call
-
Foundation Medicine to Present at the Morgan Stanley Global Healthcare Conference
-
Foundation Medicine Adds New Immunotherapy Features to Its Market-Leading Products
-
Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights
-
FoundationOne® Accepted by FDA and CMS for Parallel Review and FDA Expedited Access Pathway
-
Foundation Medicine Announces Timing for Second Quarter 2016 Financial Results and Conference Call
-
Foundation Medicine Announces Release of Molecular Information from FoundationCORE™ to the National Cancer Institute in Support of the National Cancer Moonshot and Precision Medicine Initiatives
-
New Data from Foundation Medicine and Collaborators Supports Use of Comprehensive Genomic Profiling to Inform Therapeutic Choices in Advanced Breast Cancer
-
Data From a Study Utilizing FoundationOne® Heme Indicates Age-Associated Genomic Profiles in Acute Myeloid Leukemia
-
Foundation Medicine Presents New Data at ASCO 2016 Demonstrating that FoundationOne® May Help Predict Response to Cancer Immunotherapy Across a Variety of Advanced Cancers
-
FoundationOne® Identifies Patients with Advanced Lung Cancer Likely to Respond or Develop Resistance to Certain RET Inhibitor Therapies
-
Foundation Medicine and AstraZeneca Enter Strategic Collaboration for Lynparza Companion Diagnostic Assay
-
Foundation Medicine to Present at the Goldman Sachs Annual Healthcare Conference
-
Foundation Medicine (FMI) Says ASCO 2016 Presentations Will Happen; Offers Details
-
Foundation Medicine Announces Presentations at ASCO
-
Foundation Medicine Receives Patent Covering Fundamental Methods in Comprehensive Genomic Analysis in Cancer
-
Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights
-
Foundation Medicine Announces Commercial Launch of Liquid Biopsy Assay, FoundationACT™
-
Foundation Medicine and AstraZeneca Collaborate to Develop Companion Diagnostic Assays in Oncology
-
Foundation Medicine to Present at Upcoming Investor Conferences
-
Foundation Medicine’s Molecular Information Supports Discovery of Precision Therapeutics for Pediatric Cancers
-
Foundation Medicine Announces Timing for First Quarter 2016 Financial Results and Conference Call
-
New Data with FoundationOne® Supports Clinical Utility and Improved Outcomes from Molecularly Matching Non-Small Cell Lung Cancer Patients to Targeted Therapy
-
Foundation Medicine and Memorial Sloan Kettering Publish Validation Data for FoundationOne® Heme in the Journal Blood
-
Foundation Medicine Announces Presentations at the AACR Annual Meeting 2016
-
Foundation Medicine Presents New Data at the 2016 USCAP Annual Meeting Underscoring Importance of Comprehensive Genomic Profiling in Cancer Care
-
Foundation Medicine to Present at Cowen and Company’s 36th Annual Healthcare Conference
-
Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE™ to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers
-
Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook
-
Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2015 Financial Results and Conference Call

